Skip to main content
. 2022 Nov 22;17(11):e0276462. doi: 10.1371/journal.pone.0276462

Fig 6. Lung targeting increases therapeutic potency of TGF-β blockade.

Fig 6

Two days after bleomycin exposure, rats were treated iv with 833c, 833cX&Freso, 833c&Freso, or fresolimumab at the indicated doses (μg/kg). BALf was collected on day 3. Total leukocytes (A) and neutrophils (C) per ml of BALf. Percent (%) inhibition of leukocyte (B,E) and neutrophil (D,F) accumulation in BALf. (E,F) 833c&Freso (solid circles), fresolimumab (solid triangles). Graphs and statistical analysis as in Fig 3. Data were pooled from 1 to 4 independent experiments with n = 5–20 rats per group.